IL6 and atherosclerosis: Clinical and pre-clinical evidence support the pivotal role of chronic inflammation and endothelial dysfunction in accelerating the process of atherosclerosis, driven by proinflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) (12, 13).